Skip to content

Botulinum toxin type A

Botulinum toxin type A is the most important serotype in current clinical practice. It underpins the largest global brands, the broadest regulatory footprint, and the majority of therapeutic as well as aesthetic use cases.

Type A dominates because it combines a predictable onset, clinically useful duration, and broad evidence across multiple indications. It is the toxin type behind products such as Botox, Dysport, Xeomin, and Nabota / Jeuveau.

Like other botulinum toxins, type A enters cholinergic nerve terminals and suppresses acetylcholine release. The resulting weakening of targeted muscle activity, or reduction in glandular signaling, is temporary and localized when injection is properly performed.

For the shared biology behind this process, see botulinum toxin mechanism of action, botulinum toxin diffusion, and botulinum toxin immunogenicity.

Type A products are central to treatment of:

They are also extensively used in aesthetic facial treatments.

Potency units are product-specific. A unit of one type A brand should not be assumed equivalent to a unit of another type A brand without context from clinical studies, labeling, or established treatment protocols. For a practical cross-brand reading of that issue, see unit interpretation and dose calculation overview.

Because type A anchors most brand and indication nodes in the current graph, the practical layer around storage and handling and safety and adverse-effect framing is also largely a type A reading aid. Those pages help explain why dominant market presence does not remove product-specific handling or risk differences.

Compared with botulinum toxin type B, type A has wider commercial penetration and more familiar use in aesthetics. A broader comparison is available in Differences between botulinum toxin types.